EPTN International Neurological Contouring Atlas (INCA) instruction videos

function openTab(evt, tabName) { // Declare all variables var i, tabcontent, tablinks; // Trying to stop jumping to top; not working yet // (evt).click(function (e) { // var scrollHeight = (document).scrollTop(); // (this).tab(\u27show\u27); // setTimeout(function() { // (window).scrollTop(scrollHeight); // }, 5); // }); // First stop any video document.querySelectorAll(\u27video\u27).forEach(vid => vid...

EPTN International Neurological Contouring Atlas - 2021 Update

// 0) { if(slider_trans_3T_MR.getCurrentSlide() > 0){ event.stopPropagation(); event.preventDefault(); slider_trans_3T_MR.goToPrevSlide(); } } if (deltaY..

EPTN consensus-based toxicity scoring standard for the follow-up of adult brain and base of skull tumours after radiotherapy

De Roeck et al. have published a guideline for consistent toxicity scoring and follow-up in adult brain tumour patients in consensus with the European Particle Therapy Network (EPTN). The purpose of this framework is to enable the collection of uniform toxicity data of brain tumour patients treated with photon and particle therapy. This will facilitate collaboration and further propel the research field of radiation-induced toxicities relevant for these patients. In this consensus, multiple levels of recommendation are used. Level I includes all recommendations that are considered minimum..

Optimization of Brain and Head & Neck Radiotherapy

The aim of this thesis is to further optimise radiation therapy of Brain and Head & Neck by reducing the dose to the healthy surrounding tissue, so called organs at risk (OARs), leading to a reduction in side effects. The first objective of this doctoral thesis was to assess the value of proton therapy in reducing the dose to the OARs, in particular for re-irradiation in head and neck squamous cell carcinoma and primary irradiation of low-grade glioma. Chapters 2 and 3 report on two in silico trials conducted within the international Radiation Oncology Collaborative Comparison (ROCOCO)..

The posterior cerebellum, a new organ at risk?

Eekers et al. have recently proposed a neuro-oncology atlas [doi:10.17195/candat.2017.08.1, Ed.], which was co-authored by most centers associated in the European Proton Therapy Network (EPTN). With the introduction of new treatment techniques, such as integrated magnetic resonance imaging and linear accelerators (MR-linac) or particle therapy, the prediction of clinical efficacy of these more costly treatment modalities becomes more relevant. One of the side-effects of brain irradiation, being cognitive decline, is one of the toxicities most difficult to measure and predict. In order to..

EPTN consensus-based guideline for the tolerance dose per fraction of organs at risk in the brain

  EPTN consensus-based guideline for the tolerance dose per fraction of organs at risk in the brain In collaboration with the European Particle Therapy Network, a consensus table of tolerance doses for Organs at Risk in the brain was created. These values were all defined as a near maximum EQD2 values. Using the linear quadratic formula the doses are recalculated depending on the number of fractions. EQD2 = equivalent dose in 2Gy-fractions D = the total dose d = the dose per fraction α/β = were derived from literature   Please note that this table does not..

Data from: Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial

Background and Purpose Patients with low-grade glioma (LGG) have a prolonged survival expectancy due to better discriminative tumor classification and multimodal treatment. Consequently, long-term treatment toxicity gains importance. Contemporary radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), Tomotherapy (TOMO) and intensity-modulated proton therapy (IMPT) enable high-dose irradiation of the target but they differ regarding delivered dose to organs at risk (OARs). The aim of this comparative in silico study was to determine..

Data from: Developing and validating a survival prediction model for NSCLC patients through distributed learning across three countries

Purpose Tools for survival prediction for non-small cell lung cancer (NSCLC) patients treated with (chemo)radiotherapy are of limited quality. In this work, we develop a predictive model of survival at two years based on a large volume of historical patient data, as a proof of concept, using a distributed learning approach. Patients and methods Clinical data from 698 lung cancer patients, treated with curative intent with chemoradiation (CRT) or radiotherapy (RT) alone were collected and stored in 2 different cancer institutes (559 patients at Maastro clinic (Netherlands), 139 at..

Data from: 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers

Background and Purpose Quantitative tissue characteristics derived from medical images, also called radiomics, contain valuable prognostic information in several tumour-sites. The large number of features available increases the risk of overfitting. Typically test-retest CT-scans are used to reduce dimensionality and select robust features. However, these scans are not always available. We propose to use different phases of respiratory-correlated 4D CT-scans (4DCT) as alternative.  Materials and Methods In test-retest CT-scans of 26 non-small cell lung cancer (NSCLC) patients and 4DCT-scans..

ULISSE: Umbrella protocoL ISSue for oncological patiEnts

The primary and general objective of the Standardized Data Collection (SDC) for oncological patients is to facilitate the development and validation of multi-factorial prediction models for different treatment outcomes. The long term aim is to build a Decision Support System (DSS) based on validated prediction models in order to be able to personalize treatments in terms of both treatment efficacy and toxicity control. The DSS has also the objective to identify patients to be included in future randomized clinical studies stratifying the different risk classes depending on the outcomes each..